Related Experiment Video

Updated: Jun 21, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Statin use is associated with improved survival in patients with advanced heart failure receiving resynchronization

Andrew D Sumner1, John P Boehmer, Leslie A Saxon

  • 1Division of Cardiology, Lehigh Valley Health Network, Allentown, PA 18103, USA. andrew.sumner@lvh.com

Congestive Heart Failure (Greenwich, Conn.)
|July 25, 2009
PubMed

Insights

Statin use may improve survival in advanced chronic heart failure (HF) patients undergoing cardiac resynchronization therapy (CRT). Further analysis revealed a significant reduction in mortality risk for patients using statins with CRT.

Area of Science:

  • Cardiology
  • Pharmacology
  • Medical Devices

Background:

  • Advanced chronic heart failure (HF) poses significant mortality risks.
  • Cardiac resynchronization therapy (CRT) is a treatment option for select HF patients.
  • The impact of statin use on survival in HF patients receiving CRT is not well-established.

Purpose of the Study:

  • To investigate the association between statin use and all-cause mortality in patients with advanced chronic HF receiving CRT.
  • To determine if statin therapy influences survival outcomes in patients undergoing CRT-P or CRT-D.

Main Methods:

  • Retrospective analysis of 1520 patients from the COMPANION trial database.
  • Patients received either CRT alone (CRT-P) or CRT with defibrillator therapy (CRT-D).
  • Multivariable analysis was performed to control for baseline characteristics and CRT type.

Main Results:

  • 40% of patients were taking statins at baseline.
  • Unadjusted analysis showed 18% mortality in the statin group vs. 22% in the no-statin group (HR 0.85, P=.15).
  • Adjusted analysis revealed statin use was associated with a 23% relative risk reduction in mortality (HR 0.77, P=.03).

Conclusions:

  • Statin use is associated with improved survival in advanced chronic heart failure patients receiving cardiac resynchronization therapy.
  • No survival benefit was observed for statin use in patients receiving optimal pharmacologic therapy without CRT.
  • These findings suggest a potential synergistic benefit of statins in HF patients treated with CRT.

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...